PolyNovo Dirección

Dirección controles de criterios 2/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Swami Raote

Chief Executive Officer (CEO)

AU$1.7m

Compensación total

Porcentaje del salario del CEO	35.5%
Permanencia del CEO	1.8yrs
Participación del CEO	n/a
Permanencia media de la dirección	1.8yrs
Promedio de permanencia en la Junta Directiva	4.5yrs

Actualizaciones recientes de la dirección

Recent updates

When Should You Buy PolyNovo Limited (ASX:PNV)?

Feb 28

Why Investors Shouldn't Be Surprised By PolyNovo Limited's (ASX:PNV) P/S

Feb 02

PolyNovo Limited (ASX:PNV) Shares Could Be 47% Below Their Intrinsic Value Estimate

Jan 08

PolyNovo Limited's (ASX:PNV) Intrinsic Value Is Potentially 95% Above Its Share Price

Nov 01

What Does PolyNovo Limited's (ASX:PNV) Share Price Indicate?

Jul 29

PolyNovo (ASX:PNV) Is Looking To Continue Growing Its Returns On Capital

Jun 15

Estimating The Fair Value Of PolyNovo Limited (ASX:PNV)

May 16

We Think PolyNovo (ASX:PNV) Is Taking Some Risk With Its Debt

Apr 28

There's Been No Shortage Of Growth Recently For PolyNovo's (ASX:PNV) Returns On Capital

Mar 07

Is PolyNovo (ASX:PNV) Weighed On By Its Debt Load?

Dec 13

PolyNovo Limited's (ASX:PNV) CEO Compensation Looks Acceptable To Us And Here's Why

Oct 19

Is PolyNovo (ASX:PNV) Using Debt In A Risky Way?

May 08

News Flash: 7 Analysts Think PolyNovo Limited (ASX:PNV) Earnings Are Under Threat

Feb 27

Earnings Update: PolyNovo Limited (ASX:PNV) Just Reported And Analysts Are Trimming Their Forecasts

Feb 25

Is PolyNovo Limited (ASX:PNV) Potentially Undervalued?

Feb 17

These Analysts Think PolyNovo Limited's (ASX:PNV) Earnings Are Under Threat

Jan 14

Breakeven Is Near for PolyNovo Limited (ASX:PNV)

Dec 28

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Swami Raote en comparación con los beneficios de PolyNovo?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	n/a	n/a	AU$2m
Sep 30 2023	n/a	n/a	-AU$2m
Jun 30 2023	AU$2m	AU$617k	-AU$5m

Compensación vs. Mercado: La compensación total ($USD1.12M) de Swami está en línea con el promedio de empresas de tamaño similar en el mercado Australian ($USD1.01M).

Compensación vs. Ingresos: Datos insuficientes para comparar la compensación de Swami con los resultados de la empresa.

CEO

Swami Raote

1.8yrs

Permanencia

AU$1,738,130

Compensación

Mr. Swami Raote, B. Pharmacy, M.B.A, serves as Director at PolyNovo Limited since September 2022. He serves Entrepreneurs in Residence at DigitalDx Ventures. He serves as Chief Executive Officer at PolyNov...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Swami Raote	CEO & Director	1.8yrs	AU$1.74m	sin datos
Jan-Marcel Gielen	CFO & Company Secretary	5.3yrs	AU$291.63k	0.13% A$ 1.8m
David McQuillan	Chief Technical & Scientific Officer	1.6yrs	AU$624.62k	0.097% A$ 1.3m
Philip Scorgie	Chief Information Officer	less than a year	AU$249.33k	sin datos
Ahmed Hassan	Director of Operations	2.3yrs	sin datos	sin datos
Monica Benyk	Director of People	no data	sin datos	sin datos
Tim Moore	Principal Scientist	no data	AU$145.12k	sin datos
Edward Graubart	President of North America	4.6yrs	sin datos	sin datos
Joseph Amaral	Chief Medical Officer	less than a year	sin datos	sin datos

1.8yrs

Permanencia media

Equipo directivo experimentado: El equipo directivo de PNV no se considera experimentado ( 1.8 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Swami Raote	CEO & Director	1.6yrs	AU$1.74m	sin datos
Robyn Elliott	Independent Non-Executive Director	4.5yrs	AU$95.43k	0.011% A$ 148.9k
Bruce Rathie	Non-Executive Independent Director	14.2yrs	AU$95.43k	0.47% A$ 6.5m
David Williams	Independent Non-Executive Chairman	10.2yrs	AU$140.00k	3.1% A$ 42.6m
Andrew Lumsden	Independent Non-Executive Director	2.8yrs	AU$95.43k	0.022% A$ 298.5k
Leon Hoare	Independent Non-Executive Director	8.3yrs	AU$95.43k	0.17% A$ 2.3m
Christine Emmanuel-Donnelly	Independent Non-Executive Director	3.9yrs	AU$95.43k	0.039% A$ 538.8k

4.5yrs

Permanencia media

62yo

Promedio de edad

Junta con experiencia: La junta directiva de PNV se considera experimentada (4.5 años de antigüedad promedio).

PolyNovo Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

PolyNovo Limited, Annual General Meeting, Nov 03, 2023

Independent Non-Executive Chairman recently sold AU$9.7m worth of stock

Independent Non-Executive Chairman recently bought AU$202k worth of stock

PolyNovo Limited, Annual General Meeting, Oct 28, 2022

PolyNovo Limited Announces Re-Designation of David McQuillan as Chief Technical and Scientific Officer

PolyNovo Limited Announces CEO Changes

Recent updates

Now 23% undervalued

Now 20% undervalued

Price target increased by 9.7% to AU$2.14

When Should You Buy PolyNovo Limited (ASX:PNV)?

First half 2024 earnings released: EPS: AU$0.004 (vs AU$0.006 loss in 1H 2023)

Why Investors Shouldn't Be Surprised By PolyNovo Limited's (ASX:PNV) P/S

Price target increased by 7.4% to AU$1.95

PolyNovo Limited (ASX:PNV) Shares Could Be 47% Below Their Intrinsic Value Estimate

PolyNovo Limited, Annual General Meeting, Nov 03, 2023

Price target decreased by 9.5% to AU$1.88

Health Check: How Prudently Does PolyNovo (ASX:PNV) Use Debt?

Price target decreased by 7.8% to AU$2.07

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates fall by 65%, revenue upgraded

Forecast breakeven date pushed back to 2025

When Should You Buy PolyNovo Limited (ASX:PNV)?

Are Investors Undervaluing PolyNovo Limited (ASX:PNV) By 29%?

Price target decreased by 11% to AU$2.25

Forecast breakeven date pushed back to 2025

Shareholders Should Be Pleased With PolyNovo Limited's (ASX:PNV) Price

Independent Non-Executive Chairman recently sold AU$9.7m worth of stock

Is It Too Late To Consider Buying PolyNovo Limited (ASX:PNV)?

Now 23% undervalued after recent price drop

Forecast breakeven date moved forward to 2023

First half 2023 earnings released: AU$0.006 loss per share (vs AU$0.002 profit in 1H 2022)

PolyNovo Limited Announces Update on SynPath Diabetic Foot Ulcer Trial

PolyNovo Limited Announces Update on SynPath Diabetic Foot Ulcer Trial

Price target increased by 13% to AU$2.36

Consensus EPS estimates upgraded to AU$0.0002 loss

Is PolyNovo Limited (ASX:PNV) Worth AU$2.6 Based On Its Intrinsic Value?

Forecast breakeven date pushed back to 2024

Price target increased to AU$1.98

Price target increased to AU$1.90

Returns At PolyNovo (ASX:PNV) Are On The Way Up

PolyNovo Limited's (ASX:PNV) Intrinsic Value Is Potentially 95% Above Its Share Price

Independent Non-Executive Chairman recently bought AU$202k worth of stock

PolyNovo Limited, Annual General Meeting, Oct 28, 2022

PolyNovo Limited Announces Re-Designation of David McQuillan as Chief Technical and Scientific Officer

Price target increased to AU$1.68

Full year 2022 earnings: EPS misses analyst expectations

Now 21% undervalued

PolyNovo Limited Announces First Patient Enrolled in Clinical Trial of NovoSorb SynPath Treatment for Diabetic Foot Ulcers

PolyNovo Limited Announces CEO Changes

PolyNovo Limited Announces CEO Changes

What Does PolyNovo Limited's (ASX:PNV) Share Price Indicate?

Consensus forecasts updated

Now 21% undervalued

PolyNovo (ASX:PNV) Is Looking To Continue Growing Its Returns On Capital

Independent Non-Executive Chairman recently bought AU$956k worth of stock

Now 23% undervalued

Estimating The Fair Value Of PolyNovo Limited (ASX:PNV)

Independent Non-Executive Chairman recently bought AU$434k worth of stock

We Think PolyNovo (ASX:PNV) Is Taking Some Risk With Its Debt

Price target decreased to AU$1.57

Consensus forecasts updated

There's Been No Shortage Of Growth Recently For PolyNovo's (ASX:PNV) Returns On Capital

Price target decreased to AU$1.70

First half 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus forecasts updated

Price target decreased to AU$2.04

Is PolyNovo (ASX:PNV) Weighed On By Its Debt Load?

PolyNovo Limited's (ASX:PNV) CEO Compensation Looks Acceptable To Us And Here's Why

PolyNovo Limited Announces First Patient Enrolled in Pivotal Trial of the BARDA Funded Burn Study

Full year 2021 earnings released

Price target decreased to AU$2.48

PolyNovo Limited Provides an Update on its Hernia Device

Is PolyNovo (ASX:PNV) Using Debt In A Risky Way?

Non-Executive Independent Director recently sold AU$571k worth of stock

Price target increased to AU$2.92